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A critical question in the ﬁeld of allogeneic hematopoietic stem cell transplantation (HSCT) is how to enhance
graft-versus-leukemia (GVL) activity while limiting graft-versus-host-disease (GVHD). We have previously
reported that donor bone marrow (BM) precursors of plasmacytoid dendritic cells (pre-pDCs) can polarize
donor T cells toward Th1 immunity and augment the GVL activity of donor T cells while attenuating their
GVHD activity in a murine model of allogeneic HSCT. Clinical data on the role of donor pre-pDCs and
conventional DCs (cDCs) on transplantation outcomes has been conﬂicting. To test the effect of increasing the
proportion of pre-pDCs versus cDCs in a BM graft, we enriched CD11b pDCs by selectively depleting the
CD11bþ myeloid DC (mDC) population from BM using FACS sorting in a murine model of allogeneic BM
transplantation. Donor T cell expansion and GVL activity were greater in mice that received BM depleted of
mDCs compared with mice that received undepleted BM. GVHD was not increased by depleting mDCs. To
examine the mechanism through which mDC depletion enhances the GVL activity of donor T cells, we used
BM and pDCs from IL-12p40KO mice, and found that the increased GVL activity of mDC-depleted BM was IL-
12edependent. This study indicates that a clinically translatable strategy of engineering the DC content of
grafts can improve clinical outcomes in allogeneic HSCT through the regulation of donor T cell activation and
GVL activity.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Donor T cells mediate the graft-versus-leukemia (GVL)
effect, but also cause graft-versus-host disease (GVHD) after
allogeneic hematopoietic stem cell transplantation (HSCT).
Both GVL and GVHD require antigen-presenting cells (APCs)
to activate Tcell effectors [1,2]. In contrast to the requirement
for host dendritic cells (DCs) in the initiation of GVHD [3], the
role of donor DCs in transplantation outcomes is less clear.
We previously reported that recipients of bone marrow
(BM) grafts from HLA-matched related donors containing
fewer precursors of plasmacytoid DCs (pre-pDCs) had less
relapse andmore chronic GVHD compared with patients that
received larger numbers of pre-pDCs [4]. More recently, in
analysis of the BMTCTN0201 clinical trial, we reexamined the
role of donor pDCs in the context of unrelated donor trans-
plants [5]. Donors and recipients were randomized to receive
either BM allografts or granulocyte colony-stimulating
factoremobilized blood stem cell grafts from unrelated
donors, 25% of which were HLA-mismatched. In an analysis
of subsets of immune cells in the BM grafts, we found that
recipients of grafts containing more immature donor pDCs
and donor-naïve CD8þ T cells had improved survivaldgments on page 1338.
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13.06.016compared with recipients of grafts containing fewer of these
cell subsets [5,6].
The present study was undertaken to further explore the
role of donor pre-pDCs and classical DCs in allogeneic HSCT
outcomes using established murine BM transplantation
(BMT) models. Murine DC subsets have a functional corre-
spondence but incomplete phenotypic identity with human
DC subsets. Both human and murine pDCs are important in
initiating innate immunity [7,8], and murine BM-derived
pDCs produce signiﬁcant amounts of IL-12 and polarize
T cells toward Th1 immune responses in vitro [8-11]. Human
DC subsets are distinguished by different patterns of
phenotypic markers than murine DCs. Human conventional
DCs (cDCs) produce proinﬂammatory cytokines when
activated, and it has been suggested that human cDCs
are the equivalent of mouse myeloid DCs (mDCs;
LinCD11cþCD11bCD8aþ) [12]. Although some studies have
shown that human cDCs produce large quantities of IL-
12p70, suggesting that they are the functional analog of
murine pDCs, Mittag et al. [13] recently reported that both
pDCs and cDCs from human spleen can produce IL-12p70,
and also perform functions primarily restricted to murine
pDCs, such as cross-presentation. MacDonald et al. [14]
previously showed that depleting CD11cþ cDCs reduced the
severity of GVHD in mice, and donor cDCs are the most
effective population for presenting alloantigen and stimu-
lating naïve donor T cells responses early after BMT [15].
Recently, our group reported that the addition of donor
BM cells enriched for pre-pDCs to a graft composed
of puriﬁed hematopoietic stem cell (HSCs) and T cellsTransplantation.
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without increasing GVHD compared with treatment solely
with donor HSCs and T cells [16]. Transplantation of FACS-
sorted donor pre-pDCs added to puriﬁed HSCs and donor
T cells resulted in Th1 and Tc1 immune polarization of donor
T cells with higher serum levels of IL-12, IFN-g, and IL-2 at
3 and 10 days post-transplantation comparedwith recipients
of HSCs and T cells alone [16].
To establish the mechanism by which different donor
DC subsets regulate post-transplantation immunity, we
explored the role of IL-12 produced by donor DCs in the
augmentation of the GVL activity of donor T cells in a murine
BMTmodel. Based on themarkedly higher serum levels of IL-
12 in the recipients of BM enriched for pre-pDCs, we
hypothesized that passive enrichment of pDCs by depleting
mDCs from a BM graft might enhance the GVL activity of
donor T cells, and that IL-12 synthesized by donor pDCs may
be necessary for enhanced activation and GVL activity of
donor T cells.
This study was designed to test whether selective and
speciﬁc depletion of a rare BM DC subset would have
signiﬁcant clinical outcomes in a murine model of BMT. To
test this hypothesis, we used 2 allogeneic murine BMT
models, C57BL/6/B10.BR and C57BL/6/FVB. We report
that recipients of mDC-depleted BM had increased donor
T cell proliferation, engraftment, and survival post-
transplantation without increased GVHD compared with
recipients of undepleted BM in tumor-bearing mice.
Enhanced proliferation and engraftment of donor T cells was
not seen with mDC-depleted BM from IL-12p40KO donors.
These data show that selective pDC enrichment in BM allo-
grafts enhances donor T cell engraftment and GVL activity.
The beneﬁcial effects of mDC depletion appear to be IL-
12edependent.
MATERIALS AND METHODS
Mice
B10.BR (H-2Kk, CD45.2, CD90.2), C57BL/6 (B6, H-2Kb, CD45.2, CD90.2),
FVB/NJ (H-2q, CD45.1, CD90.1), and PepBoy (B6.SJL-PtprcaPep3b/BoyJ)(H-2Kb,
CD45.1, CD90.2) mice on a B6 background and IL-12p40KO (IL-12KO) mice
(B6.129S1-Il12btm1Jm/J) (H-2Kb, CD45.2, CD90.2) were purchased from Jack-
son Laboratory (Bar Harbor, ME). Congenic strains expressing CD90.1 and
CD45.2 on a B6 (H-2Kb) background (BA), and expressing CD90.1 and CD45.2
on a B10 (H-2Kk) background (BA.B10) were backcrossed 10 generations to
the parental strain and bred at the Emory University Animal Care Facility
(Atlanta, GA). The luciferase-expressing transgenic mice on a B6 background
were bred at Emory University. Mice were used at age 8-12 weeks. Proce-
dures conformed to National Institutes of Health animal care guidelines and
were approved by Emory University’s Institutional Animal Care and Use
Committee.
Cell Preparations
Donor mice were killed in a humane manner, and femurs, tibias, and
spleens were removed aseptically. BM cells and splenocytes were harvested
with sterile PBS. T cells were puriﬁed by incubating splenocytes with bio-
tinylated anti-CD11b, anti-B220, anti-CD49b, and anti-TER119 antibodies
(BD Biosciences), followed by anti-biotin microbeads, and negative
magnetic-activated cell sorting (MACS) selection using an LS magnetic
column (Miltenyi Biotech, Gladbach, Germany).
For CD11bþ mDC depletion from T celledepleted (TCD) BM grafts, BM
cells were incubated with biotin-conjugated anti-CD3 antibodies (BD
Biosciences, San Jose, CA), followed by anti-biotin microbeads (Miltenyi
Biotech). TCD BMwas then collected using an LS magnetic column (Miltenyi
Biotech) and stained with a cocktail of antieCD11c-FITC, antieCD11b-APC-
Cy7, and anti-Lineage (Lin) (IgM, CD19, CD49b and TER119)-PE antibodies.
Lin- CD11cþ CD11bþ cells were depleted by FACS using a FACSAria cell sorter
with Diva software (BD Biosciences). After initial scatter-based gating for
viability, the Lin and Linþ populations were identiﬁed and further gated on
CD11c and CD11b; CD11cþCD11bþ double-positive cells were discarded. All
other Lin- and Linþ cells were sorted for transplantation and compose the
CD11bþ mDC-depleted BM population.For FACS sorting of HSCs and pDCs, harvested BM was stained with
cocktails of biotinylated Lin (CD3, CD19, TER119, IgM, CD49B, and CD11b),
PE-conjugated Lin (CD4, CD8, Gr1, Iab), antiePDCA1-V450, antieB220-
PeCy5, antieCkit-APC, antieSca1-PeCy7, and antieCD11c-FITC. HSC and
pDCs were sorted as described by Lu et al. [17].
Tumor Cells
LBRM 33-5A4, a B10 T cell lymphoma cell line [18], was purchased from
American Type Culture Collection (ATCC; Manassas, VA). Tumor cell lines
were cultured in accordance with ATCC recommendations. Tumor cell lines
were tested to be free of lymphocytic choriomeningitis virus, mouse
hepatitis virus, mouseminute virus, andmouse parvovirus by the University
of Missouri Research Animal Diagnostic Laboratory (Columbia, MO). This cell
line was transfected to express luciferase in our laboratory and was used in
the in vivo bioluminescent imaging (BLI) experiments.
Transplantation
On day -2 before transplantation, recipient B10.BR mice received a total
of 11 Gy irradiation, divided into 2 doses of 5.5 Gy given 3 hours apart [19].
On day 0, recipient mice were injected i.v. with combinations of 1  106 or
3  106 mDC-depleted TCD BM cells and 3  105 or 1  106 MACS-puriﬁed
T cells from B6 donors in a B6B10.BR model. For tumor experiments,
recipient B10.BR mice received an i.v. dose of 5  105 cells of viable
luciferase-positive LBRM 33-5A4 on day -1. For puriﬁed HSC, pre-pDC, and
T cell transplants, on day 0 recipient mice were injected i.v. with combina-
tions of 3000 FACS-sorted HSCs, 50,000 FACS-sorted pre-pDCs, and 3  105
MACS-puriﬁed T cells from B6 donors.
All transplant recipients were monitored for survival and clinical signs
of GVHD daily. Mice were scored for clinical signs of GVHD based on weight
loss, posture, activity, fur texture, and skin integrity twice weekly for the
ﬁrst 30 days and weekly thereafter, as described by Cooke et al. [20].
According to Institutional Animal Care and Use Committee protocol, mori-
bund mice, mice with >25% weight loss, and mice surviving until the end of
the experiment were euthanized and considered to have died on the day
after euthanasia for the analysis of post-transplantation survival.
T Cell Proliferation, Intracellular Cytokine Expression, and Serum
Cytokines
The proliferation of donor T cells in recipient spleen was analyzed with
the intracellular ﬂuorescent label carboxyﬂuorescein diacetate succinimidyl
ester (CFSE; Molecular Probes, Eugene, OR) to tag proliferating cells. Donor T
cells were stained with CFSE before transplantation. Recipient spleens were
removed on day þ3.5, and cell suspensions were prepared. Proliferation of
donor T cells was determined by ﬂow cytometry analysis of CFSE dilution
proﬁles gated on the donor T cell population [21]. Intracellular cytokine
expression (IL-4, IL-10, IL-17, TNF-a, and IFN-g) by CD4þ and CD8þ T cells
was analyzed using the Cytoﬁx/Cytoperm Kit (BD Biosciences) as described
previously [22]. Appropriate isotype controls were used for all intracellular
targets. All samples were analyzed on a FACSCanto ﬂow cytometer (BD
Biosciences), and list mode ﬁles were analyzed using FlowJo software (Tree
Star, Ashland, OR).
Serum and Secreted Cytokine Levels
Serumwas harvested and stored at 20C until use in cytokine analysis
by ELISA (OptEIA ELISA kit for IFN-g or Ready-SET-Go ELISA kit for IL-13
[eBioscience, San Diego, CA]). ELISA plates were read using a SpectraMax
340PC spectrophotometer (Molecular Devices, Sunnyvale, CA).
In Vivo BLI
In vivo BLI was performed using a cooled charge-coupled device (CCD)
camera system (IVIS Imaging System 100; Xenogen, Alameda, CA). The mice
received a subcutaneously injection of D-luciferin (0.15 mg/g body weight;
ﬁreﬂy luciferin potassium salt; Xenogen, Alameda, CA). Ten minutes later,
mice were placed in the light-tight chamber of the CCD camera system
under anesthesia with rodent cocktail (ketamine 20 mg/mL and xylazine 2.5
mg/mL, 0.1 mL/25 g body weight), and photographic and luminescent
images in the ventral projection were acquired using a 3-minute exposure
time. Up to 5 mice were imaged simultaneously. On each in vivo BLI image,
a region of interest (ROI) encompassing the entire mouse was created, and
the whole-body signal in the ROI (photons/second) was quantiﬁed using
Living Image version 3.2 (Xenogen). The whole-body bioluminescent signal
served as a marker of donor T cell burden.
Statistical Analyses
Data analyses were performed using SPSS version 18 for Mac (IBM,
Armonk, NY) or Prism version 5 for Mac (GraphPad Software, San Diego, CA;
www.graphpad.com). Data are presented as mean  SD of all evaluable
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Kaplan-Meier or Mantel-Cox log-rank test in a pairwise fashion. Differences
in GVHD outcome between groups were compared using the Kruskal-Wallis
test. Differences in the levels of T cell CFSE division, bioluminescence ROI
values, and numbers between groups and other parametric tests were
compared using 1-way analysis of variance followed by a Bonferroni post-
test. A P value < .05 was considered signiﬁcant. In BLI quantiﬁcation data,
signiﬁcant outliers were removed using the Grubbs’ test for outliers.RESULTS
Increasing the Ratio of pDCs to mDCs Enhances GVL
Our previous experiments demonstrated increased
survival in tumor-bearing mice that received puriﬁed HSCs,
T cells, and pre-pDCs compared with mice that received
puriﬁed HSCs and T cells alone [16]. The strategy of trans-
planting multiple FACS-puriﬁed subsets from BM grafts is
not practical in clinical practice. To model the selectiveFigure 1. Depletion of mDCs enhances GVL in an IL-12edependent manner. (A and B
from BM cells by incubating BM cells with biotinylated anti-CD3 antibody and then ant
column. Total nucleated cells were gated on Lin markers (CD3, Ter119, DX5, IgM, and C
CD11cþCD11bþ double-positive cells were discarded. The gray bold line represents gat
for transplantation and compose the CD11bþmDC-depleted BM population. The perce
and after sorting (B) are shown. (C-F) Survival (C and E) and mean GVHD clinical score
plus 3  106 undepleted BM cells or FACS-sorted mDC-depleted BM cells from IL-12K
group). (E and F) Recipients were injected with 5  105 viable luciferase-positive LBR
*P < .05 and ***P < .001 represent a log-rank comparison of survival of tumor-bear
depleted BM or undepleted BM, respectively. In (F), *P < .05 comparing IL-12KO mD
unpaired 2- tailed t-test. Survival and GVHD data are from a single experiment withdepletion of a BM DC subset, we developed a FACS gating
strategy to passively enrich Lin CD11cþ CD11b pDCs by
selectively depleting the LinCD11cþ CD11bþ mDCs from
the BM graft while preserving the content of HSCs, T cells, B
cells, monocytes, natural killer cells, and pre-pDCs
(Figure 1A and B). The content of Lin-CD11bþCD11cþ mDCs
was depleted by 99%, whereas the recovery of the other cell
subsets was > 95% (data not shown). The CD11bþCD11cþ
mDCs represent average frequencies of 0.3%  0.03% of the
nucleated BM cells from WT mice and 0.4%  0.17% of those
from IL-12p40KO mice. The CD11cþCD11b DC subpopula-
tion represents average frequencies of 0.7%  0.15% of
murine BM cells from WT mice and 0.8%  0.29% of those
from IL-12p40KO mice. Thus, the average ratio of pDCs to
mDCs was approximately 2-3:1 in both WT and IL-12p4KO
mice (data not shown).) Gates for sorting CD11bþ mDC-depleted BM cells. CD3þ T cells were depleted
i-biotin microbeads, followed by negative MACS selection using an LS magnetic
D19), followed by CD11b and CD11c. Lin- cells were gated on CD11c and CD11b.
ing for excluding double-positive cells. All other Lin- and Linþ cells were sorted
ntages of Lin- cells with an mDC phenotype (CD11bþCD11cþ) before sorting (A)
s (D and F) of mice that received 1  106 MACS-puriﬁed Pepboy splenic T cells
O or WT donors in C57BL/6J B10.BR transplantation model (n ¼ 6-10 mice per
M tumor cells on day 1, 1 day after irradiation, and 1 day before BMT. In (E),
ing recipients of WT mDC-depleted BM with recipients of IL-12p40KO mDC-
C-depleted BM with WT mDC-depleted BM on day 15 post-transplantation,
each group comprising 10 experimental mice.
Figure 2. Donor T cell proliferation is increased in mDC-depleted BM recipients in an IL-12edependent manner. Lethally irradiated CD45.2þ B10.BR mice received
1 106 CFSE-labeled CD45.1þ T cells from Pepboy donors with 3  106 undepleted BM cells or FACS-sorted mDC-depleted BM cells from IL-12p40KO orWT B6 donors.
Recipient splenocytes were prepared on day 3.5 post-transplantation and analyzed for the proliferation of donor T cells. (A) Average percentage of cells in each
division peak. ***P < .001; ****P < .0001 comparing percentages of undivided T cells in different times in IL-12p40KO and WT mDC-depleted recipients; *P < .05
comparing percentages of divided T cells in WT undepleted and mDC-depleted recipients. (B) Mean  SD percentages of T cells that had undergone 6-7 cell divisions.
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Figure 3. Serum IFN-g and IL-13 levels are increased in recipients of mDC-depleted BM. Lethally irradiated CD45.2þ B10.BR mice received 3  105 CD45.1þ T cells
from Pepboy donors with 3  106 undepleted BM cells or FACS-sorted mDC-depleted BM cells from IL-12KO or WT B6 donors. (A-D) Recipient splenocytes were
prepared on day 10 post-transplantation and analyzed for the percentages of intracellular cytokine-producing donor T cells of IFN-g (A; P ¼ NS), TNF-a (B; P ¼ NS), IL-
10 (C; P ¼ NS), and IL-17 (D). For the CD4 data, **P < .01 comparing WT mDC-depleted and IL-12p40KOmDC-depleted recipients, For the CD8 data, *P < .05 comparing
WT mDC-depleted and IL-12p40KO mdC depleted recipients. (E and F) Serum was also collected and analyzed for levels of IFN-g (E) and IL-13 (F). For (E), *P < .05
comparing WT undepleted and WT mDC-depleted recipients. For (F), **P < .01 comparing WT undepleted and WT mDC-depleted recipients, unpaired 2-tailed t-test.
Data are compiled from 2-3 independent experiments with n ¼ 3 per group.
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grafts on the GVL activity of donor T cells, we used an
established C57BL/6 to B10.BR transplant model and the
B10.BR tumor cell line LBRM, which was stably transfected
with luciferase. B10.BR mice were lethally irradiated and
given 1  106 WT B6 T cells along with 3  106 undepleted
BM cells or mDC-depleted BM cells from WT B6 or IL-
12p40KO donors, as we described previously [16]. Clinical
GVHD scores were monitored twice weekly post-
transplantation, as described by Cooke et al. [20]. Survival
of mice was monitored daily. In nonetumor-bearing mice
that received allogeneic BM and T cells, no signiﬁcant
difference in survival or GVHD score was seen among the
different treatment groups (Figure 1C and D).
We next examined whether selective depletion of mDCs
from a murine BM allograft would augment donor T cell
activation and GVL activity. B10.BR mice were lethally irra-
diated and given 5105 LBRM cells at 1 day after irradiation.
Two days after irradiation, mice were transplanted with
1  106 WT B6 T cells along with 3  106 undepleted BM
cells or mDC-depleted BM cells from WT B6 or IL-12p40KO
donors. Mice receiving mDC-depleted BM had signiﬁcantly
increased survival (median survival, 49 days) compared with*P < .05; **P < .01 comparing the 2 groups. Data are representative of 1 of 2 indepe
CD45.2þ B10.BR mice that received 1  106 luciferase-positive T cells from C57BL6/J do
from IL-12KO or WT B6 donors or undepleted BM cells, showing luciferase-positive do
5, 7, 14, 21 and 30 post-transplantation. The color bar showss the scale used for the ps
per group. (D) Whole-body images in which total signal in the ROI (photons/secon
comparing ROI of WT mDC-depleted and IL-12p40KO mDC-depleted groups at day 3mice receiving either undepleted BM (median survival,
21.5 days) or IL-12p40KO mDC-depleted BM (median
survival, 32 days) (Figure 1E). GVHD scores were not signif-
icantly different among the groups, except on dayþ15, when
the mice receiving IL-12p40KO mDC-depleted BM had
a signiﬁcantly higher GVHD score than mice receiving WT
mDC-depleted BM (Figure 1F). Mice receiving mDC-depleted
BM from IL-12p40KO recipients experienced signiﬁcantly
greater weight loss than mice receiving WT mDC-depleted
BM from days 12-17 post-transplantation, which correlates
with the higher GVHD scores received by IL-12p40KO
recipient mice (data not shown). Weight loss also could be
related to increased tumor burden, as demonstrated by the
fact that the IL-12p40KO mice had the lowest median
survival in a tumor model, but not in a nontumor model.
Depletion of mDCs Results in Early Increased
Proliferation and Expansion of Donor CD8þ T Cells in an
IL-12eDependent Manner
We next used CFSE-labeled T cells to test the effects of
enriching pDCs in BM grafts on early alloreactive donor T
cell proliferation in the spleen. A large number of CD8þ T
cells in the spleen at early time points post-transplantationndent experiments with n ¼ 3 per group. (C) BLI images of lethally irradiated
nors with 3  106 undepleted BM cells or FACS-sorted mDC-depleted BM cells
nor T cell expansion in allogeneic recipients. BLI images were obtained on days
eudocolor image. Images are representative of a single experiment with n ¼ 5
d) was measured on post-transplantation days 5, 7, 14, 21 and 30. **P < .01
0. Data are compiled from 2 independent experiments with n ¼ 5 per group.
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leukemia model [23]. Lethally-irradiated B10.BR mice
received 1106 CFSE-labeled T cells from CD45.1þ congenic
Pepboy (B6 background) donors, in combinationwith FACS-
sorted 3  106 undepleted BM cells or mDC-depleted BM
cells from IL-12p40KO or WT B6 donors. Figure 2 shows the
level of donor T cell proliferation on day 3.5 post-
transplantation, as assessed by CFSE dilution in the spleen
of transplant recipients. Of note, there was a signiﬁcant
increase in the proliferation of donor CD8 T cells in the
recipients of mDC-depleted BM compared with recipients
of undepleted BM (P < .01) (Figure 2A and B). This is similar
to our previously reported ﬁndings in mice in which all
CD11bþ cells in the BM were depleted and mice in which
pDCs were added to puriﬁed HSCs and T cells, and indicates
that the residual pDC component of the marrow augments
T cell proliferation. The role of donor pDC-derived IL-12 in
enhancing T cell proliferation was conﬁrmed by results
showing no enhanced proliferation of donor T cells after
selective depletion of themDC component inmice receiving
IL-12p40KO BM.
The expansion of donor T cells in recipients of undepleted
BM, mDC-depleted BM, and IL-12p40KO mDC-depleted BM
is shown in Figure 2C. In this case, luciferase transgenics
were used as the donor T cell source to track the in vivo
expansion of donor T cells. We transplanted 3  105
luciferase-positive T cells in combination with 3  106 mDC-
depleted BM cells from either IL-12p40KO or WT C56BL/6
mice, or undepleted BM cells fromWT B6 donors into B10.BR
mice after lethal irradiation. Whole-body bioluminescent
images of mice were obtained at days 5, 7, 14, 21, and 30, and
the total bioluminescence signal (in photons/second) was
determined per mouse.
The data showed homing of donor T cells initially to the
spleen on day 5 post-transplantation, with subsequent
expansion in the abdominal cavity on days 7-30 (Figure 2C).
Comparing T cell proliferation as assessed by emitted
photons, we identiﬁed a trend toward greater T cell expan-
sion in the recipients of mDC-depleted BM on day 5 and
a signiﬁcant difference in the overall level of T cell expansion
by day 30, with lower numbers of donor T cells in the group
receiving IL-12p40KO BM (P < .05) and undepleted BM
(P¼ not signiﬁcant [NS]) (Figure 2D). These data indicate that
IL-12eproducing donor DCs may augment the alloreactivity
of donor T cells, similar to a the ﬁndings reported by
Anderson et al. [24] indicating a role for donor DCs in CD4-
mediated GVHD of the gut. The lower levels of T cell prolif-
eration seen in the recipients of IL-12KO mDC-depleted BM
are consistent with the role of donor-derived IL-12 in
promoting Th1 polarization of T cells and contributing to
GVHD at later time points post-transplantation.
Effect of mDC Depletion on the Production of
Inﬂammatory Cytokines
We hypothesized that mDC depletion also would polarize
donor T cells toward a Th1 phenotype, and thus examined
intracellular cytokine production by splenic donor T cells and
serum cytokines on day 10 post-transplantation. Both the
percentages and median ﬂuorescence intensity of IFN-ge,
TNF-ae, and IL-10eproducing CD4 and CD8 T cells did not
differ signiﬁcantly among recipients of undepleted BM, WT
mDC-depleted BM, and IL-12p40KO mDC-depleted BM
(Figure 3A-C; data not shown). However, IL-12p40KO mDC-
depleted BM recipients had signiﬁcantly higher percentages
of IL-17eproducing CD4 and CD8 donor T cells in the spleenon day 10 post-transplantation (P < .01 and < .05, respec-
tively; Figure 3D). IL-17 has been implicated as contributing to
CD4-mediated GVHD, which is consistent with increased
GVHD in the IL-12p40KO mDC-depleted BM recipients at day
15 post-transplantation (Figure 1F). The mice receiving WT
mDC-depleted BM also had signiﬁcantly higher serum IFN-g
levels (Figure 3E). IL-12 did not seem to play a role in this
increased production, as demonstrated by the high serum
levels of IFN-g in mice that received mDC-depleted BM from
IL-12p40KO mice. This was in agreement with previous ﬁnd-
ings of increased production of Th1 cytokines in mice that
underwent transplantation with puriﬁed populations of HSC,
pDC, and T cells [16]. Finally, serum IL-13 levels were signiﬁ-
cantly higher in mice receiving mDC-depleted BM compared
with those receiving undepleted BM (P < .01; Figure 3F).
Serum IL-13 level was not measured in mice receiving IL-
12p40KO mDC-depleted BM. IL-13 has been shown to
generate myeloid-derived suppressor cells (MDSCs) that can
reduce GVHD without impairing GVL [25]. We have also seen
this phenomenon in mice receiving puriﬁed populations of
HSCs, pre-pDCs, and T cells compared with mice receiving
HSCs and T cells alone (unpublished data, Waller laboratory).
IL-12 Production by Pre-pDCs Prolongs Survival in
Tumor-Bearing Mice Receiving HSCs, Puriﬁed pre-pDCs,
and T Cells
Although we found increased survival in mice receiving
mDC-depleted BM in a tumor-bearing model, which seemed
to be IL-12p40edependent, we hypothesized that IL-12e
producing pDCs remaining in the BMwere responsible for the
enhanced GVL activity of donor T cells. To conﬁrm this
hypothesis, we transplantedmicewith puriﬁed populations of
HSCs, pre-pDCs (CD11cþCD11b-B220þPDCA1þ), and T cells.
Mice were lethally irradiated and received 1  106 luc-LBRM
cells i.v. at 1 day after irradiation. At 1 day after tumor injec-
tion, mice underwent transplantation with FACS-sorted
combinations of 3000 WT HSCs, 50,000 pre-pDCs from
either WT or IL-12p40KO mice, and 3  105 WT T cells, or
a combination of 3  106 BM cells with 3  105 WT T cells as
a control. All radiation control mice died within 12 days post-
transplantation (data not shown). Mice receiving HSCs alone
experienced 0% survival, with a median survival of 14 days
(Figure 4A). Mice receiving HSCs, WT pre-pDCs, and T cells
had 75% survival at 40 days post-transplantation, slightly
higher than that in mice receiving whole BM and T cells
(Figure 4A). All mice receiving HSCs, IL-12p40KO pre-pDCs,
and T cells died, with a median survival of 12 days. We spec-
ulate that the lack of IL-12p40 production early after trans-
plantation may result in rapid death from acute GVHD.
Surviving mice underwent imaging at 36 days post-
transplantation for luciferase-positive tumors. Of the
surviving mice, only 15% of mice receiving WT BM and T cells
had no detectable tumor, as determined by photons emitted
from the tumor, whereas 34% of mice receiving HSCs,WT pre-
pDCs, and T cells had no detectable tumor. The tumor light
signal emanating from eachmousewas quantiﬁed (Figure 4B).
Although not signiﬁcant, mice receiving BM and T cells had
a higher average bioluminescent signal compared with mice
receiving HSCs, WT pre-pDCs, and T cells (Figure 4B).
DISCUSSION
Ineffective GVL and the development of acute and chronic
GVHD limit the broad application of allogeneic BMT. Based
on clinical reports that the content of donor pDCs in alloge-
neic BM grafts is associated with survival [4], we developed
Figure 4. IL-12p40eproducing pre-pDCs confer a survival advantage to
tumor-bearing mice undergoing transplantation with puriﬁed population of
HSCs, pre-pDCs, and T cells. CD45.2þ B10.BR mice were lethally irradiated and
received 1  106 luciferase-positive LBRM cells i.v. on day 1 after irradiation.
On day 2 after irradiation, mice underwent transplantation with 3000 FACS-
sorted HSCs (Lin-Sca1þCkitþ), 50,000 WT (C57BL/6J) or IL-12p40KO
(Lin-CD11cþCD11b-B220þPdca1þ) pre-pDCs, and 3  105 T cells. A control
group received 3 106 total BM cells and 3 105 T cells. (A) The mice receiving
HSCs, WT pre-pDCs, and T cells had increased survival compared with those
receiving HSCs, IL-12p40KO pre-pDCs, and T cells. *P < .05, log-rank compar-
ison of survival. (B) Whole-body images of surviving mice were obtained on
day þ36 post-transplantation, and total signal in the ROI (photons/second)
was determined (P ¼ .56 comparing recipients of BM þ T cells and recipients of
HSCs þWT pDCs þ T cells, unpaired 2-tailed t-test). Data are representative of
1 of 2 independent experiments (n ¼ 4-7 per experimental group). Statistical
analyses were conducted on survival data combined from both replicate
experiments.
K.A. Darlak et al. / Biol Blood Marrow Transplant 19 (2013) 1331e1339 1337murine model systems to test whether selective alteration in
the relative numbers of donor pre-pDCs versus donor mDCs
favorably improves the balance between GVL and GVHD in
allogeneic BMT. Initially we reported that depletion of all
CD11bþ cells (including CD11bþ DCs, CD11bþ natural killer
cells, and MSPCs) from the donor BM enhanced the anti-
tumor activity of allograft donor T cells without signiﬁcantly
increasing GVHD in mice [26]. Later, using highly puriﬁed
populations of donor pDCs, we observed that transplanting
puriﬁed pDCs along with HSCs and T cells leads to Th1
polarization of donor T cells and improved GVL activity
compared with transplanting HSCs, mDCs, and T cells, or
HSCs and T cells alone [16], and demonstrated the bidirec-
tional signaling between donor T cells and donor pDCs with
IFN-g produced by donor T cells inducing indoleamine 2,3-
dioxygenase (IDO) synthesis by donor pDCs limited GVHD
[17]. However, the approach of sorting puriﬁed populations
of cells is impractical from a clinical translation standpoint.
In the present study, we sought to develop a clinically
translatable approach of graft engineering that would result
in the same GVL improvement.
We passively enriched the relative content of donor
pDCs:mDCs in the BM allograft by selectively depleting
CD11bþ DCs with high-speed FACS to test whether depletion
of mDCs from BM grafts has a similar effect as positive
addition of pDCs of grafts consisting of puriﬁed populations
of HSCs and T cells. We found that tumor-bearing micereceiving mDC-depleted BM had increased survival without
an increase in GVHD. Mice receiving mDC-depleted BM have
increased donor T cell proliferation at early time points (day
3) in the spleen in vivo, especially donor CD8þ T cell
proliferation. Using BLI, we found that on day 30 post-
transplantation, recipients of mDC-depleted BM had
a greater number of luciferase-positive donor T cells overall.
Recipients of mDC-depleted BM from IL-12p40KO donors did
not exhibit expansion and proliferation of donor T cells,
suggesting that the effects of mDC-depleted BM on donor
T cell proliferation and expansion are IL-12edependent. To
conﬁrm that IL-12p40 produced by pDCs is responsible for an
increased GVL effect, we transplanted puriﬁed populations of
HSCs, pre-pDCs from either WT or IL-12p40KO donors, and
T cells. Mice receiving HSCs, WT pre-pDCs, and T cells had
increased survival compared with mice receiving HSCs, IL-
12p40KO pre-pDCs, and T cells [16].
These data are consistent with our previous reports on
the role of pDCs in donor immunity after allogeneic HSCT.
Donor CD8þ T cells have been identiﬁed as an important
mediator of GVL effect [27]. Fowler and coworkers [28,29]
previously showed that allogeneic CD8þ T cells generated
by in vitro allo-antigenic priming in the presence of IL-12
mediate more potent GVL effects than those primed in the
presence of IL-4. In previous studies, in a tumor model we
found that adding donor pDCs to puriﬁed HSCs and T cells
increased T cell proliferation after transplantation as well as
survival compared with transplantation of HSCs, mDCs, and
T cells or HSCs and T cells alone [16]. There ares reports of
CD11bþCD11cþDCs with a tolerogenic phenotype. In amodel
of i.v. tolerance in experimental autoimmune encephalo-
myelitis (EAE), mice immunized i.v. with a myelin oligo-
dendrocyte glycoprotein peptide after induction of EAE had
less severe EAE than mice immunized with PBS, and had
abundant CD11cþCD11bþ DCs in the spleen and central
nervous system. These CD11cþCD11bþ DCs were capable of
inhibiting proliferation of myelin oligodendrocyte glyco-
proteinespeciﬁc T cells, enhancing the development of Th2
cells as well as enhancing regulatory T cell generation [30].
These tolerogenic CD11bþDCs also demonstrated reduced IL-
12 production and enhanced IL-10 production on coculture
with Tcells and lipopolysaccharides [30]. CD11bþCD11cþDCs
expressing high levels of IDO also have been found in orally
tolerized mice in a collagen-induced arthritis model [31].
These CD11bþ IDOþ DCs could suppress collagen-speciﬁc
T cell proliferation as well as induce regulatory T cells [31].
In previous studies, adding donor pDCs to puriﬁed HSCs
resulted in polarization of donor T cells toward Th1 and Tc1
immune responses with higher serum levels of IL-12, IFN-g,
and IL-2 and higher numbers of IFN-geproducing donor
T cells [16]. Based on signiﬁcant Th1 polarization of donor
T cells induced by cotransplantation of FACS-puriﬁed donor
pDCs, higher serum levels of IL-12 reported by our group [16],
and the potent ability of IL-12 to stimulate Th1/Tc1 cells [32],
we hypothesized that Th1 polarization of donor T cells
induced by mDC-depleted BM might be IL-12edependent. In
this study, however, we found no signiﬁcant differences in the
production of Th1/Tc1 cytokines by donor T cells in the
presence or absence of IL-12eproducing pDCs [33-35].
Of note, the IL-12KO mice used were IL-12p40KO,
resulting in the absence of IL-12p70, IL-12p80, and IL-23
expression. IL-23 is produced by APCs after BMT and has
been suggested to induce subsequent expression of IL-22,
which is reduced by the presence of GVHD [36]. A deﬁ-
ciency of recipient-derived IL-22 leads to increased GVHD as
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pathology. Thus, interpretation of the results obtained with
IL-12p40KO mice as donors must account for the potential
role of IL-23 as well.
Interestingly, mice receiving mDC-depleted BM had
signiﬁcantly higher levels of serum IL-13 at 10 days post-
transplantation. Highﬁll et al. [25] reported that MDSCs
generated in the presence of IL-13 can inhibit GVHD, migrate
to sites of allopriming, and limit the activation and prolifer-
ation of donor T cells, but do not diminish the GVL effect of
donor T cells. We propose that IL-13 might be a mechanism
by which mice receiving mDC-depleted BM experience
higher survival in a tumor-bearing model without increased
GVHD.
Another potential mechanism by which enrichment of
pDCs may augment GVL without increasing GVHD is through
the production of IFN-a by pDCs. Robb et al. [37], using mice
deﬁcient in the IFNAR1 component of the type I IFN receptor,
found that type I IFN signaling prevented GVHD in
CD4mediated models of GVHD. Interestingly, type I IFN
signaling in donor cells enhanced CD8-dependent GVHD and
GVL and augmented donor cytotoxic T lymphocyte function
[37]. Although the source of IFN-a in a BMT setting is unclear,
pDCs are the most potent producers of type I IFNs after viral
infection [38].
The present study was designed to explore more
a feasible and translatable graft engineering strategy for
regulating the relative numbers of pDCs and mDCs and to
improve the efﬁcacy of allogeneic BMT. Our data show that
pDC enrichment of BM allografts consistently enhanced
donor T cell expansion, donor CD8þ T cell proliferation, and
GVL activity, and that the beneﬁcial effects of pDC enrich-
ment were dependent on IL-12. Taken together, our data
support the idea that selective depletion of an immune-
phenotypically deﬁned DC subset from a murine BM graft
is a novel and feasible method for manipulating the BM graft
to regulate donor T cell activation and enhance GVL activity
without leading to increased GVHD. Moreover, we have
demonstrated that IL-12 is a key cytokine synthesized by
donor pDCs that is necessary for augmentation of GVL
activity of donor T cells in a murine allogeneic BMT model.
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